- Home
- MGNX vs NEGG Comparison
MGNX vs NEGG Comparison
Compare MGNX & NEGG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- NEGG
- Stock Information
- Founded
- MGNX 2000
- NEGG 2001
- Country
- MGNX United States
- NEGG United States
- Employees
- MGNX N/A
- NEGG N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- NEGG Other Specialty Stores
- Sector
- MGNX Health Care
- NEGG Consumer Discretionary
- Exchange
- MGNX Nasdaq
- NEGG Nasdaq
- Market Cap
- MGNX 70.3M
- NEGG 75.6M
- IPO Year
- MGNX 2013
- NEGG 2010
- Fundamental
- Price
- MGNX $1.43
- NEGG $4.01
- Analyst Decision
- MGNX Hold
- NEGG
- Analyst Count
- MGNX 10
- NEGG 0
- Target Price
- MGNX $6.83
- NEGG N/A
- AVG Volume (30 Days)
- MGNX 599.1K
- NEGG 33.3K
- Earning Date
- MGNX 05-20-2025
- NEGG 04-28-2025
- Dividend Yield
- MGNX N/A
- NEGG N/A
- EPS Growth
- MGNX N/A
- NEGG N/A
- EPS
- MGNX N/A
- NEGG N/A
- Revenue
- MGNX $149,962,000.00
- NEGG $1,235,576,000.00
- Revenue This Year
- MGNX N/A
- NEGG N/A
- Revenue Next Year
- MGNX $80.86
- NEGG N/A
- P/E Ratio
- MGNX N/A
- NEGG N/A
- Revenue Growth
- MGNX 155.26
- NEGG N/A
- 52 Week Low
- MGNX $0.99
- NEGG $3.32
- 52 Week High
- MGNX $14.91
- NEGG $26.40
- Technical
- Relative Strength Index (RSI)
- MGNX 43.37
- NEGG 45.45
- Support Level
- MGNX $1.54
- NEGG $3.40
- Resistance Level
- MGNX $1.82
- NEGG $4.20
- Average True Range (ATR)
- MGNX 0.15
- NEGG 0.31
- MACD
- MGNX 0.01
- NEGG 0.14
- Stochastic Oscillator
- MGNX 19.79
- NEGG 77.84
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally.